Maternal thyroid hormones are transcriptionally active during embryo–foetal development: results from a novel transgenic mouse model

Citation

Published Version
doi:10.1111/j.1582-4934.2009.00947.x

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15035029

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Introduction

Tetraiodothyronine (T4) is secreted by the thyroid gland as a prohormone that is converted in the tissues to triiodothyronine (T3), the active hormone that binds to the nuclear receptors and initiates thyroid hormone (TH) action [1]. In extrathyroidal tissues,
T3 concentration in the intracellular and nuclear compartments is dependent on (i) the circulating levels of THs, (ii) their rates of entry and exit in and out of the cell and the nucleus, (iii) the rate of T4 to T3 conversion and (iv) T3 degradation in the cell [2]. The formation and degradation of T3 in tissues are dependent primarily on the activities of three selenodeiodinases (type 1, type 2 and type 3) that catalyse the selective removal of iodine from iodothyronines and convert the precursor T4 into the active hormone T3, and the inactive hormones reverse T3 and T2 [3]. Importantly, the cellular uptake and the release of THs are mediated by transporters. Among these, monocarboxylate transporter 8 (MCT8) is particularly important in the transport of T3 into the brain [4, 5].

THs are necessary for differentiation, growth and metabolism in mammals as well as lower organisms [6]. Its biological action is mediated by thyroid hormone receptors (TRs) binding to TH-responsive elements (TREs) in the regulatory regions of target genes that regulate gene transcription by chromatin remodelling [7, 8]. In the absence of TH, TRs bind a complex of inhibitory proteins that promote deacetylation and inhibit gene transcription [9]. Recently another mechanism by which the nuclear corepressor NCoR modulates expression of positive TRs targets and regulates the response to set levels of T3 was demonstrated [10].

Both T4 and T3 have been importantly detected in the rat embryo and foetal brain before the onset of foetal thyroid function (FTF) [11, 12]. T4 has been found in human embryonic cavities in the first trimester of pregnancy, thus suggesting that maternal T4 could cross the placenta. From the coelomic fluid it may reach the embryo via the yolk sac, and may be functionally important for the developing embryo, while its own thyroid is not yet functioning [13]. In addition, significant levels of total T4 were found in umbilical cord sera of term neonates affected by congenital hypothyroidism, unable to produce any T4 due to total iodide organification defects. After birth, T4 serum levels gradually decreased, and became undetectable within 2 weeks, thus indicating that substantial amounts of T4 are transferred from mother to foetus during late gestation [14]. Nuclear T3 receptor has been interestingly found in human foetal brain, liver, heart and lung at early and mid gestation [15, 16].

Indeed, maternal THs have been consistently described to play a crucial biological role in brain development, affecting dendritic elongation and branching of Purkinje cells, synaptogenesis, proliferation and migration of granule cells, and myelination [7, 17]. Both maternal hypothyroidism and hyperthyroidism have deleterious effects on the outcome of human pregnancy [18]. High maternal THs levels (not associated with autoimmune thyroid disease), by itself, produce foetal thyrotoxicosis, impair embryogenesis and cause higher miscarriage rates through a direct toxic effect of excess THs on the human foetus [18].

Furthermore, maternal thyroid failure even in terms of hypothyroxinemia alone (reduced FT4 and normal TSH levels), or subclinical hypothyroidism may be harmful to the human foetus. In fact, several rodent models demonstrated that maternal hypothyroidism may have different effects in the offspring: (i) severe defects in the cerebral and cerebellar cortex, and in visual and auditory development [7, 19–21]; (ii) inappropriate gene expression in foetal rat brain [22, 23] and (iii) alterations in cell migration in the cerebral cortex and hippocampus [19, 24, 25].

Maternal hypothyroxinemia is 150–200 times more prevalent than congenital hypothyroidism and results in lack of TH in embryo–foetal primordia during early pregnancy, before the onset of FTF [26, 27]. Severe iodine deficiency during pregnancy may induce maternal and foetal hypothyroxinemia, and cause neurological dysfunctions in the progeny [28–32]. Importantly, permanent alterations in the cytoarchitecture of the cerebral cortex appear in the progeny of hypothyroxinemic but not in hypothyroid dams [33].

The hypothesis that maternal THs can interact with embryonic TRs is supported by two facts: (i) maternal T4, which is essential for the development of the brain and other foetal organs was found in coelomic and amniotic fluid in human beings and other species before FTF became active [25, 34]; (ii) TRs are expressed in the cerebral cortex of first trimester human foetuses [15, 35], as well as in rodent embryonic and adult neural tissues [36–38]. However, direct evidence to support a physiological interaction between maternal TH and embryonic TRs during the early and late stages of embryogenesis is still lacking [25].

To address this question, transgenic mouse models expressing the LacZ reporter gene (encoding β-galactosidase [β-gal]) under a TRE, have been generated to specifically trace maternal TH transgene activity during early and late embryo–foetal development.

Materials and methods

Engineering the transgenic vector TRE2×

to generate TRE2× we used a truncated enhancer region (MBP-TRE-18) of the native myelin basic protein (MBP-TRE-33) gene promoter [39–41]. We chose this sequence (MBP-TRE-18) and configuration because it provides a selective and robust response to TRs (TRβ1, TRα1) [39]. TRE2× containing two MBP-TRE-18 [39, 40] spaced by two nucleotides (gc) was cloned into the pNASSβ vector (generously provided by Dr. G. Piaggio, Regina Elena Cancer Institute, Roma, Italy) expressing LacZ reporter gene in order to create pTRE2×. The structure of pTRE2× is shown in Fig. 1A. The following forward and reverse oligonucleotides were used for vector generation: 5'-CTTCGAGAAGCTTACCTCGAGTCGGAGGC-ACGGctACCTCGGAGTAGACGAGG-3' and 5'-GATCCCGTCTCACGAGTACGAGGAC- GTgcGGTtCGTCTCACGAGGAGTAAGCTTACCTCGAGTCGGAGGC-ACGGctACCTCGGAGTAGACGAGG-3', respectively. These comprised (from 5'- to 3') four restriction sites, Sphi, XhoI, HindIII and BamHI, and two TRE-18 spaced by two base pairs (bp) (gc). The resulting double-stranded oligo was digested and subcloned into the Sphi site downstream of TK minimal promoter of the pBLCAT2 vector [39]. A TK construct (named pNASSβ-TK), deleted of the MBP-TRE-18 sequences, was used as a negative control. All plasmids were checked by automated DNA sequence analysis.
**Cell transfections**

NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% foetal calf serum (FCS) (Sigma, St. Louis, MO, USA). Cell transfections were performed by electroporation according to Desvergne et al. [42], in the presence of hormone-free FCS-supplemented medium. Briefly, 6 μg of pTRE2× or pTK along with 12 μg of each of the following nuclear receptor plasmid were electroporated using the Bio-Rad GenePulser at 960 μf-arcades and 250 V: rat TRα1, rat TRβ1, mouse oestrogen receptor (ERα) and ER-β (generously provided by Dr. A. Farsetti), mouse TRβ2, retinoic X receptors (RXR)α and RXR-γ (generously provided by Dr. P. Yen, Johns Hopkins Bayview Medical Center, Baltimore, USA), mouse RXR-β (generously provided by Dr. C. Gaetano, Istituto Dermopatico dell'Immacolata, Roma, Italy), or mouse retinoic acid receptor (RAR)α and RAR-β (generously provided by Dr. M. Cippitelli, Regina Elena Cancer Institute, Roma, Italy).

**Transgenic mouse models**

**Animal care**

Animal care procedures were conducted in accordance with the guidelines of the European Community Council Directives (86/609/EEC). Animals were cared for in accordance with the guidelines of the European Community Council Directives (86/609/EEC).
were kept under controlled temperature (22 ± 2°C) and light (12 hrs light: 12 hrs dark cycle; lights on at 07:00 am) conditions, and had free access to food and water.

**Transient transgenic embryos (transient transgenic model)**

Linearized pTRE2× (named TRE2×) was injected into (C57Bl/6xDBA/2)F2 zygotes as described by Nagy et al. [43]. After zygote implantation, foster mothers were killed at embryonic day 9.5 (E9.5), E10.5, E11.5, E12.5, E13.5 (early embryo development) and E15.5 and E17.5 (late embryo development) in order to analyse TRE2× genome integration and β-gal expression.

**Stable transgenic mice**

To generate stable transgenic lines, linearized TRE2× transgene was injected into (C57Bl/6xDBA/2)F2 zygotes as described by Nagy et al. [43]. One founder (out of 60 pups) was identified by PCR and homozygous mice were analysed by quantitative real-time PCR.

Transgenic embryos derived from homozygous mice matings were collected at E9.5, E10.5, E11.5, E12.5, E13.5, E15.5 and E17.5, and analysed for TSH, total T3 and T4 levels according to Pohlenz et al. [46]. TSH was measured in 50 μl serum using a sensitive, heterologous dis-equilibrium double-antibody precipitation RIA [46]. The minimal detectable concentrations in the assay were 10 mIU/l for TSH, 3.21 nmol/l for total T4 and 0.15 nmol/l for total T3. All mouse sera in this study were assayed for TSH activity by a blind tester.

This animal study was approved by Institutional Review Board (Regina Elena Cancer Institute, Rome, Italy).

**Screening of transgenic mice by PCR**

Genomic DNA was extracted from mouse placenta or mouse tail biopsies by the addition of 1% SDS, 50 mM Tris-HCl (pH 8.0) and 10 mg/ml of proteinase-K (Invitrogen, San Giuliano Milanese, Italy), and incubated overnight at 55°C. DNA was purified by phenol-chloroform extraction and ethanol precipitation. TRE2× and TK transgenic embryos were screened by PCR using the following primers, respectively: (i) TRE2×-Forward-5′-ACCTCGGCTGAGGACACGGCACC-3′ and LacZ-Reverse-5′-GGCCGTAACCGACCCAGCGCCGCG-3′ that amplify the DNA region comprised between the TRE-TK (enhancer-promoter region) and LacZ sequences and (ii) TK-Forward-5′-GGATCCGGCGCCGGAGCTCT-3′ and LacZ-Reverse-5′-GGCCGTAACCGACCCAGCGCCGCG-3′ that amplify the region between the TK promoter and LacZ sequences. PCR analysis was carried out on 200 ng genomic DNA by TAQ polymerase (Invitrogen). After 40 cycles (1 min at 95°C, 1 min. at 67°C and 1 min. at 72°C) the PCR products of TRE2× and TK were analysed on a 0.8% agarose gel. As positive controls for TRE2× and TK transgene amplicons, we used the pNASSp and pBLCAT2 vectors, respectively. As negative control, we used genomic DNA without LacZ gene sequences.

**Genotyping assay by real-time PCR**

Homozygous mice were identified by quantitative real-time PCR and confirmed by breeding test. The breeding test was performed by mating between homozygous mice and wild-type mice. Quantitative real-time PCR was performed according to Shih et al. [44] on genome DNA of different founders in order to quantify TRE2× copy number. LacZ primers (forward: ACCTCGGCTGAGGACACGGCACC and reverse: GCTGATGTT) were designed using the Primer Express oligo design soft-

**Hypothyroidism**

Hypothyroidism was induced in TRE2× transgenic female mice according to Schneider et al. [45] by treatment with 0.1% 2-mercapto-1-methylimidazole (MMI) (Sigma) and 1% potassium perchlorate (KClO₄) (Sigma) dissolved in deionized water and administered by oral gavage (200 μl per day) for approximately 4–6 weeks. In addition, low iodine diet (LID) was used. TRE2× transgenic female mice were continuously treated with 0.1% MMI and 1% KClO₄, beginning approximately 4–6 weeks before pregnancy induction and with 0.1% MMI alone combined with LID from E11.5 until the end of pregnancy they were treated.

Serum total T4 and T3 concentration were measured by coated tube radioimmunoassay (RIA) (Diagnostic Products, Los Angeles, CA, USA) adapted for mouse serum using 25 and 50 μl serum, respectively [46]. TSH was measured in 50 μl serum using a sensitive, heterologous dis-equilibrium double-antibody precipitation RIA [46]. The minimal detectable concentrations in the assay were 10 mIU/l for TSH, 3.21 nmol/l for total T4 and 0.15 nmol/l for total T3. All mouse sera in this study were assayed for TSH activity by a blind tester.

This animal study was approved by Institutional Review Board (Regina Elena Cancer Institute, Rome, Italy).

**Treatment with T3**

We treated 14 hypothyroid transgenic mice (TRE2×−/−) with L-T3 (Sigma-Aldrich, Milan, Italy) (1.5 μg/100 g body weight per day) by intraperitoneal injections for 4 days (from E9.5 to E12.5). As control group, 14 hypothyroid transgenic mice (TRE2×+/−) received the vehicle alone. The animals were killed at E12.5. Transgenic embryos were collected and stained for β-gal activity (β-gal expression). Blood samples were collected 6 hrs after the last T3 dose from the tail or cava veins. The sera were tested for TSH, total T3 and T4 levels according to Pohlenz et al. [46].

**β-gal enzymatic assay in embryos**

β-gal activity assay (β-gal expression) was carried out on E9.5, E10.5, E11.5, E12.5 and E13.5 transient and stable embryos as described by Vernet et al. [47]. Briefly, embryos were fixed using 1% paraformaldehyde, 0.2% glutaraldehyde, 2 mM MgCl₂, 5 mM EGTA and 0.02% NP40 in PBS (pH 7.3) for 30–90 min. at 4°C. After several washes in 0.02% NP40 in PBS, they were stained at 37°C overnight in the dark using 5 mM K₃Fe(CN)₆, 5 mM K₄Fe(CN)₆.3H₂O, 2 mM MgCl₂, 0.02% NP40, 20 mM Tris-HCl (pH 7.3) and 1 mg/ml X-gal dissolved in PBS. β-gal protein was stable overnight at 37°C according to Nagy et al. [43]. Embryos were post-fixed in 4% paraformaldehyde/PBS for 12–24 hrs, dehydrated in an ascending series of alcohols, embedded in paraffin and sectioned on the coronal or sagittal planes at 10 μm. Embryos at E15.5 and E17.5 were embedded in OCT compound (Biopica, Milan, Italy) and frozen in cold isopentane, and β-gal histochemistry was performed on frozen tissue.
sections as described by Signoretti et al. [48]. Finally, selected β-gal stained sections of E9.5, E10.5, E11.5, E12.5, E13.5, E15.5 and E17.5 embryos were processed for immunohistochemical analysis.

Immunohistochemistry

Ten-micrometre-thick sagittal or coronal sections of E9.5, E10.5, E11.5, E12.5, E13.5, E15.5 and E17.5 transient and stable embryos were obtained with a Leica sliding microtome and mounted in series on superfrost slides. One series was counterstained with 1% neutral red, cover slipped in Eukitt mounting medium and photographed to describe the distribution of β-gal + areas. The others series were used for immunohistochemistry (IHC) using antibodies against TRs, RXRs and RAR. To localize TRs, sections were processed at room temperature (r.t.). They were incubated in 0.3% H2O2 in 0.1 M PB-saline (PBS) for 30 min. in order to inhibit endogenous peroxidases and then washed in PBS. Sections were transferred for 1 hr into PBS containing 0.3% Triton X-100, 10% normal goat serum and 3% bovine serum albumin. Sections were incubated overnight (TRs) or for 48 hrs (RXRs and RAR) at 4°C in a solution containing a rabbit polyclonal antibody against TRα1, TRβ1, TRβ2, RXR-α, RXR-β, RXR-γ (generously provided by Dr. P. Yen, Johns Hopkins University, USA) or RAR-α (sc-551, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Binding of the primary antibody was visualized by incubating the tissue with biotinylated goat anti-rabbit IgG (Vector, Burlingame, CA, USA; diluted 1:200 in PBS-T) for 4 hrs at r.t., followed by an avidin-biotin-peroxidase complex (Vector Laboratories, Elite ABC Kit, Burlingame, CA, USA) for 2 hrs at r.t.; the peroxidase was detected using 3,3′-diaminobenzidine tetrahydrochloride (DAB, Sigma) or 3-Amino-9-ethylcarbazole (AEC, Dako, Glostrup, Denmark) as chromogen. After cover slipping in Mowiol, sections were observed using a Nikon Eclipse E-800 light microscope and photographed by a Coolpix 990 digital camera (Nikon, Cefalù Firenze, Italy).

Paraffin-embedded sections of rat pituitary were used as positive controls for TRs. For RXR and RAR families rat pituitary and liver paraffin-embedded sections were used. The specificity of the antiserum, certified by the manufacturer, was validated by omitting the antiserum from the incubation medium. In addition, as a further negative control for TRs we used pituitary paraffin-embedded tissues from mice TRα1+/− and Pax8−/− (female number 268 and male number 280) and TRβ2−/− and Pax8−/− (female number 166 and male number 183), kindly provided by Dr. Heike Heuer (‘Neuroendocrinology’ Leibniz Institute, Jena). The colocalization between β-gal activity (blue staining) and nuclear receptors expression was evaluated by immunoreacting E9.5, E10.5, E11.5, E12.5 E13.5, E15.5 and E17.5 embryos, previously reacted for β-gal in whole mount, on 10-μm-thick sagittal or coronal serial sections. Because DAB precipitates upon treatment with any of these ligands (data not shown).

Transgenic expression in euthyroid transient embryos derived from TRE2× microinjection (transient model)

Upon TRE2× injection into (C57Bl/6xDBA2/F2) zygotes followed by implantation (implanted zygotes = 921) into 72 euthyroid female mice (body weight = 24 g ± 0.3). Euthyroid mice showed values of TSH less than 10 mU/l, T4 51.60 nmol/l and T3 1.14 ± 0.09 nmol/l. TRE2× transactivation (β-gal expression) was analysed in 175 embryos (E9.5, E10.5, E11.5, E12.5, E13.5 and E17.5) (Table 1). Examples of β-gal + transient transgenic embryos are shown in Fig. 2. TK+ transient transgenic embryos, used as negative controls, did not show any β-gal expression (data not shown).

Maternal TH action during early stages of development in euthyroid transient transgenic embryos

At E9.5 no β-gal staining was detected (Fig. 3A). TRs IHC at E9.5 showed weak expression of TRα1, TRβ1 and TRβ2 in the midbrain and medulla oblongata (Fig. 3B–D). On the contrary, retinoic receptors (both RXR and RAR) were highly expressed (data not shown).

Transgenic embryos from euthyroid mice showed consistent β-gal expression in the same anatomical sites, as early as E11.5–E12.5. At E11.5–E12.5, the staining was localized in different
primordial anatomical areas (Fig. 4), i.e. cerebellum, mesencephalon and myelencephalon. In particular, β-gal was highly expressed in the diencephalic vesicle (epithalamus, dorsal wall of the III ventricle) and in the mantle layer of alar plate of the lateral wall of the metencephalon, in the medulla oblongata, the marginal and mantle layers of the lateral wall of the midbrain, the mantle layer of the lateral wall of the spinal cord, the ocular annexa and the retina, the vestibular primordia (semicircular canal and endolymphatic sac) and in the trigeminal ganglion. Interestingly, the presumptive trigeminal ganglion, facial ganglion, vestibulococlear ganglion complex, inferior ganglion of the vagal nerve, the hypoglossal nerve, the sympathetic chain and the roots of the spinal nerves expressed high levels of β-gal. In contrast, β-gal protein expression was rarely detected in the ventricular layer of the telencephalon. In the skeleton, β-gal protein expression was found in the mesenchymal head of the palatine process, the maxillary process, the bones of the upper limb and in the myotomal muscle mass. In the circulatory system, β-gal was detected in the internal carotid, the sixth arch and the mesenteric arteries. A line of positive cells was also observed surrounding the abdominal aorta towards the gut. Moreover, β-gal expression was weakly detected in the liver, the stomach, the duodenum, the dorsal mesentery of the hindgut, the mesenchymal tissue surrounding

Table 1 β-gal expression in TRE2× positive transgenic embryos during early (E9.5, E10.5, E11.5, E12.5 and E13.5) and late (E15.5 and E17.5) stages of development

<table>
<thead>
<tr>
<th>Number of mice</th>
<th>Development</th>
<th>No. of transient transgenic embryos &quot;β-gal expression&quot;</th>
<th>No. of embryos from stable transgenic mice &quot;β-gal expression&quot;</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>aE9.5</td>
<td>0/30</td>
<td>0/20</td>
</tr>
<tr>
<td>12</td>
<td>aE10.5</td>
<td>0/30</td>
<td>0/20</td>
</tr>
<tr>
<td>12</td>
<td>aE11.5</td>
<td>7/20</td>
<td>15/15</td>
</tr>
<tr>
<td>12</td>
<td>aE12.5</td>
<td>33/75</td>
<td>20/20</td>
</tr>
<tr>
<td>12</td>
<td>aE13.5</td>
<td>4/10</td>
<td>12/12</td>
</tr>
<tr>
<td>12</td>
<td>aE15.5</td>
<td>-</td>
<td>8/8</td>
</tr>
<tr>
<td>12</td>
<td>aE17.5</td>
<td>4/10</td>
<td>13/13</td>
</tr>
</tbody>
</table>

E = embryonic day; a = early development; b = late development. "β-gal expression was consistently detected in the same anatomical sites of transgenic embryos derived from TRE2× positive transgenic mice (see text). No ectopic sites of β-gal expression were observed. *Thyroid foetal function is active.
the trachea and oesophagus, the atria and in the umbilical cord. Skin primordia (dermatomes) also showed β-gal expression (data not shown).

TRs IHC in β-gal-anatomical areas showed intense labelling for TRβ1 and TRβ2, and weak labelling for TRα1, RXR-α, RXR-β, RXR-γ and RAR-α (Fig. 5). RXRs and RAR-α protein expression was unchanged compared to E9.5–E10.5 (data not shown).

Nuclear receptors expression in the early stages of development

At E11.5–E12.5 TRα1 IHC shows an intense labelling in the central nervous system (CNS) primordia and colocalizes with β-gal staining (Fig. 5). This was not seen in the ocular and vestibular annexes, nor in the peripheral nervous system, which were negative for TRα1 IHC. Telencephalic vesicles were instead labelled by TRα1 IHC but not by β-gal. TRβ1 IHC displayed a similar intense labelling of cell bodies in the CNS (Fig. 5), with the exception of the spinal cord. In addition, we observed TRβ1 colocalization with the β-gal staining around blood vessels and the airways. Similarly, TRβ2 IHC gave an intense staining in the CNS primordia, even in the spinal cord (Fig. 5), and in the sense organs primordia (data not shown). On the contrary, RXR-α always gave the lightest labelling, except for some labelling in the spinal cord (motoneurons) and in the spinal nerve roots, without colocalization with β-gal staining (data not shown). RXR-β IHC stained the CNS with less intensity than TRα1 and TRβ1 (Fig. 5). In this case, labelling was colocalized with β-gal staining only in the optic nerve, whereas colocalization was almost absent in the brain and in the spinal cord. RXR-γ IHC gave a weak staining, with a low degree of colocalization with β-gal staining in the brain with no staining outside the brain (Fig. 5).

TH action during late stages of development in euthyroid transient transgenic embryos

At late stages of development (E15.5–E17.5), when FTF (E17.5) is active and the embryo is at the trilaminar disc stage, β-gal expression was exclusively detected: (i) in the small intestine primordia (Fig. 6); (ii) in the vibrissal follicular nerves (maxillary and mandibular divisions of the trigeminal cranial nerve) (Fig. 6); (iii) in the scapula and rib cartilage primordia (ossification centres) (data not shown) and (iv) in the Meckel’s cartilage (data not shown).

Nuclear receptors expression in the late stages of development

At E17.5 TRs IHC staining was intense and colocalized with β-gal staining in the small intestine primordia (i.e. TRα1 immunoreactivity), the nerves of the whiskerpad, the follicles of the vibrissae (Fig. 6) and in the scapula and cartilage primordia (data not shown). In the cerebral cortex, TRα1 was detected (Fig. 6), in the cortical plate and in the subventricular zone, whereas it was less intense in the subplate. An intense immunoreactivity was also detected in the hippocampus and in the striatum, and some positivity was also observed in the developing ear and spinal cord. TRβ1 and TRβ2 IHC gave similar results (Fig. 6). TRs immunoreactivity was also evident in β-gal areas (i.e. in the telencephalon). RXR-β (Fig. 6) and RXR-γ (data not shown) immunoreactivities were very weak, whereas RAR-α expression was intense (Fig. 6). RXRs expression was unmodified at E17.5 compared to the early stages examined, whereas RAR-α expression was strongly increased (Fig. 6).

β-gal expression in euthyroid embryos generated from a transgenic line (stable model)

We generated a transgenic line responsive to TH action, which was able to stably express β-gal protein in the early and late stages of development. We used a transgenic line with stable expression of β-gal protein, which allowed us to detect the expression of nuclear receptors in different tissues and developmental stages. The results showed that nuclear receptors are expressed in specific anatomical areas and at different stages of development. The expression pattern of nuclear receptors varied depending on the stage of development and the tissue of interest, which could be useful for understanding the role of these receptors in normal and pathological conditions.
stages of development. TRE2× copy number in homozygous transgenic lines is reported in Fig. 7. β-gal was consistently expressed in 108 homozygous transgenic embryos both at early (E11.5, E12.5, E13.5) and late stages of development (E15.5 and E17.5) (Table 1). No β-gal expression, however, was observed at E9.5–E10.5.

Maternal TH action during early stages of development in euthyroid stable transgenic embryos

β-gal was highly expressed at early stages of development as early as E11.5–E12.5. In particular, we detected β-gal expression...
at E11.5 in the otic vesicle (wall of the endolymphatic diverticul- lar appendage) and in the diencephalon. β-gal expression was also observed at E12.5 in the diencephalon (thalamus, hypothal- amus, epithalamus, dorsal wall of the III ventricle) (Fig. 8A–C), and in the area of the future neurohypophysis, known as the infundibular recess of the third ventricle, indicated by the ecto- dermal primordium of the adenohypophysis (Rathke’s pouch). At E13.5 β-gal expression was marked in the medulla oblongata, rostral extremity of the endolymphatic duct, origin of choroid plexus differentiating from roof of fourth ventricle, choroid plexus

Fig. 5 Double labelling with β-gal and nuclear receptors IHC at E11.5 and E12.5 of euthyroid transient transgenic embryos. (A–G): IHC against thyroid (TRs) and retinoid (RXRs) recep- tors in midsagittal sections of β-gal<sup>H</sup> E11.5: (A) anti-TR<sup>α1</sup>; (B) anti-TR<sup>β1</sup> (diencephalon, medulla oblongata); (C) anti-TR<sup>β2</sup> (diencephalon, medulla oblongata); (D) anti-TR<sup>β1</sup> (diencephalon, mesencephalic vesicle); (E) anti-RXR- β (diencephalon); (F) anti-TR<sup>β2</sup>, detail in the area of the diencephalic vesicle; (G) anti-TR<sup>α1</sup>, detail of the medulla oblongata and cranial spinal cord. Scale bar = 1 mm in (A–E), 100 μm in (F) and 400 μm in (G). Arrows point to areas of colocalization between β-gal positivity and TR- immunoreactivity (diencephalon, medulla oblonga- gata and spinal cord), whereas arrowheads point to areas of TRs-immunoreactivity devoid of β-gal staining (pons and dorsal root ganglia). (H–N): IHC with antibodies against TRs and RXRs in coronal sections of the brains of β-gal<sup>H</sup> E12.5: (H) anti-TR<sup>α1</sup>; (J) anti-TR<sup>β1</sup>; (K) anti- TR<sup>β2</sup>; (I) anti-RXR-β; (L) anti-RXR-γ; (M) anti- TR<sup>β2</sup>, detail in the area of the developing hypo- thalamus; (N) anti-RXR-β, detail of the cranial spinal cord (as in Fig. 4D). Scale bar = 1 mm in (H–L) and 100 μm in (M, N). 1: third ventricle; 2: fourth ventricle; 3: lateral ventricle. Thin arrow points to the colocalization of β-gal and TR- immunoreactivity in the diencephalon (thala- mus), the arrowhead in the diencephalon (hypo- thalamus) and the thick arrow in the midbrain.
within central part of lumen of fourth ventricle and the area above the olfactory epithelium. At stages E11.5, E12.5 and E13.5, similar to our findings in the transient transgenic embryos, we detected TRs and β-gal colocalization in the aforementioned anatomical primordia.

TH action during late stages of development in euthyroid stable transgenic embryos

At late stages of development diencephalic differentiation is almost complete and various anatomical sites can be distinguished. The
neurohypophysis and the epiphysis are distinct as evaginations of the diencephalic wall in the hypothalamus and epithalamus, respectively. At E15.5 no β-gal expression was found in the diencephalic primordium, whereas it was detected in the primordia of follicles of vibrissae associated with lower lip, the olfactory epithelium, the zone of cartilage primordium of nasal septum and in the ossification centres of the mandible. At E17.5, β-gal activity was detectable in the wall of the medulla oblongata, the whiskerpad, the
occipital bone primordium, the vertebrae and in the small intestine primordia (Fig. 8D–L). Consistent with the results obtained at E17.5 in transient transgenic embryos, we detected TRs (i.e. TRα1 immunoeexpression in the small intestine primordia) and β-gal colocalization in the aforementioned anatomical primordia.

Hypothyroidism in pregnant TRE2× transgenic mice treated with T3

As expected, β-gal staining was not detectable in the early stages (E12.5) in 36 embryos obtained from 14 hypothyroid transgenic females mice (TSH 4.749 ± 938 mU/l, T4 29.60 ± 0.16 nmol/l, T3 0.75 ± 0.16 nmol/l) (body weight = 27 g ± 0.24). Goitres were observed in the hypothyroid mice.

Further, IHC against TRs (Fig. 9) did not show significant differences in the expression of all receptors, both at localization and intensity levels, when hypothyroid mouse embryos were compared to euthyroid mouse embryos.

In order to further validate the specificity of the TRE× transactivation by TH, we used two groups of 14 hypothyroid transgenic female mice. One group of mice was treated with T3 (1.5 µg/100 g body weight per day) from E9.5 to E12.5 while treatment with 0.1% MMI and low iodine diet were maintained. The control group was treated with the vehicle only. T3 in a dose of 1.5 µg was effective in decreasing the serum TSH levels in the hypothyroid transgenic mice to the physiological baseline levels (TSH < 10 mU/l) as well as increasing T3 levels (14.2 ± 2.71 nmol/l) and T4 levels (28.31 ± 0.08 nmol/l). The control mice on the other hand maintained a low T4 (11.06 ± 0.15 nmol/l) and low T3 (1.10 ± 0.3 nmol/l) and a high TSH (4,481.66 ± 778.2 mU/l) (P < 0.001). No β-gal expression was detected in the E12.5 transgenic embryos from the control group (Fig. 10A). Importantly, treatment with T3 in the hypothyroid mice rescued β-gal expression in the diencephalon primordium of E12.5 transgenic embryos (Fig. 10B), producing a similar pattern to that observed in the euthyroid transgenic mouse embryos.

In summary, our results show that in euthyroid condition, maternal THs are able to cross placental barrier and to be transcriptionally active through embryonic TRs as early as E11.5 (early stage) of embryo–foetal development (Fig. 11). On the contrary, transplacental transfer of maternal THs is inhibited with maternal hypothyroidism (low T4 and T3 and high TSH) (Fig. 11). Treatment with T3 in hypothyroid pregnant mice (from approximately 4–6 weeks before pregnancy until E12.5) was able to switch on the TRE2× transactivation and β-gal expression at the early stages (E12.5) of development when FTF is still not active.

Discussion

The simultaneous presence of maternal THs and nuclear thyroid receptors (TRs) during embryo–foetal development does not necessarily indicate that maternal THs are biologically active [25]. However, recent evidence shows that maternal T4 is necessary for early physiological neurogenesis [33, 50].
**Fig. 10** β-gal expression in hypothyroid stable transgenic mice treated with T3. (A) Hypothyroid transgenic mouse embryo at E12.5 treated with vehicle (negative control) did not show β-gal expression (no blue staining). (B) Hypothyroid transgenic mouse embryo at E12.5 treated with T3 (1.5 μg/100 g body weight per day) from E9.5 to E12.5 shows β-gal expression (blue staining, arrow) in the brain (diencephalon primordium). (C, low magnification and E, high magnification): neutral red staining shows absence of β-gal expression in the diencephalon primordium. (D, low magnification and F, high magnification): neutral red staining shows β-gal expression (blue staining) in the diencephalon primordium (arrow). Scale bar: (A, B) = 1 mm; (C, D) = 1 mm; (E, F) = 100 μm.

**Fig. 11** TRE2× transgenic mouse model. (A) Maternal THs cross the placental barrier as early as E11.5, before FTF is active, and transactivate the TRE2× transgene through embryonic TRs (see Fig. 1A, B). TRE2× transactivation permits β-gal expression. β-gal expression (blue staining) is used as a molecular marker to trace THs action during early (E11.5, E12.5, E13.5) and late (E15.5 and E17.5) stages of embryo–foetal development. (B) Conversely, when the maternal thyroid gland is functionally blocked (hypothyroidism: low T3 and T4 and high TSH), transplacental transfer of THs is inhibited, and TRE2× is not transactivated in the early stages of development by TRs; no β-gal expression (no blue staining) is therefore detected in the TRE2× positive transgenic embryos.
Early CNS differentiation comprised two phases: (i) neurulation and (ii) regionalization of the neural plate and segmentation (E8–E9.5–E10.5) consisting of the formation of the three primary brain vesicles and (ii) regionalization of the neural tube (i.e. diencephalon primordium, E11.5–E12.5) [54]. The lack of TRE2 transactivation before E11.5 may be related to different expression levels of TH transporters or type 2 and 3 deiodinases (D2 and D3) in the placenta during development [55–59]. Importantly, the main specific TH transporter, MCT8, has been recently identified by Friesema et al. [60], and found to be expressed in human normal placenta at 6 weeks of gestation, with evidence for increasing expression during advanced gestation [55]. In addition, human placenta expresses high levels of D3 that appears to be important in maintaining circulating and tissue levels of foetal THs exceedingly low relative to maternal or adult levels. This mechanism has led to the concept that TH levels during early and late development are tightly regulated within narrow limits to avoid either an excess or a deficiency of TH and that the D3, along with the D2, is widely responsible for this specific regulation [58]. Furthermore, Chan et al. have been reported that D2 and D3 mRNA levels and enzyme activities in human placenta were higher at early gestation than at late gestation [59]. Koopdonk-Kool et al. [61] have been reported significantly higher overall placental D3 than D2 activities at all gestations.

Our model was able to trace TH action (TH-indicator) during early and late development by the expression of β-gal (that is encoded by LacZ), generated through the transcriptional activation of a TH-dependent murine thyroid hormone response element (TRE2×), arising from the myelin basic protein gene-TRE. Our in vitro validations show that TRE2× transactivation is strongly responsive to T3 action by TRβ1, TRβ2 or TRα1, but not to other nuclear receptors and ligands such as oestrogen or retinoic acid. Previous studies also demonstrated a selective transcriptional activity on the myelin basic protein gene-TRE only by TR [39, 40, 52].

Using transgenic embryos, we show that maternal THs cross the placental barrier and are transcriptionally active during embry–foetal development in different primordia, before the onset of FTF (E15.5–E17.5). Importantly, we found β-gal expression as early as E11.5, a crucial early stage of CNS development. Previous studies detected T4 and T3 by RIA in rat embryos and placentas, as well as in amniotic fluid [11]. On the contrary, Quignodon et al. demonstrated T3 signalling at E15.5 (late stage of CNS development) in the midbrain roof by the use of a chimeric yeast Gal4 system [53].

Similar to previous results [11], our study shows that THs cross the placental barrier at an early stage (E11.5) of embryonic development; at this stage the FTF is still inactive and the embry–foetal primordia are sensitive to maternal TH action. Here, TRE2× transactivation resulted in β-gal expression in different embry–foetal primordia, particularly during the early and late development. Importantly, we observed β-gal expression in the same anatomical sites of several euthyroid transgenic embryos, whereas it was completely absent in embryos of transgenic hypothyroid mice. Thus, these results suggest that maternal THs are present and active during embry–foetal development, and that TRE2× transactivation is specifically driven by TH.

Interestingly, we did not detect β-gal expression before E11.5. This result may suggest that THs are not involved in the neurulation mechanisms, in spite of the presence of TRs at these stages. Early CNS differentiation comprised two phases: (i) neurulation and segmentation (E8–E9.5–E10.5) consisting of the formation of the three primary brain vesicles and (ii) regionalization of the neural tube (i.e. diencephalon primordium, E11.5–E12.5) [54]. The lack of TRE2 transactivation before E11.5 may be related to different expression levels of TH transporters or type 2 and 3 deiodinases (D2 and D3) in the placenta during development [55–59]. Importantly, the main specific TH transporter, MCT8, has been recently identified by Friesema et al. [60], and found to be expressed in human normal placenta at 6 weeks of gestation, with evidence for increasing expression during advanced gestation [55]. In addition, human placenta expresses high levels of D3 that appears to be important in maintaining circulating and tissue levels of foetal THs exceedingly low relative to maternal or adult levels. This mechanism has led to the concept that TH levels during early and late development are tightly regulated within narrow limits to avoid either an excess or a deficiency of TH and that the D3, along with the D2, is widely responsible for this specific regulation [58]. Furthermore, Chan et al. have been reported that D2 and D3 mRNA levels and enzyme activities in human placenta were higher at early gestation than at late gestation [59]. Koopdonk-Kool et al. [61] have been reported significantly higher overall placental D3 than D2 activities at all gestations.

However, further studies are needed to better understand the role of TH before E11.5 during mouse development.

In our study, the detection of β-gal expression at E11.5 strengthens previous studies that demonstrated that maternal THs play a critical role in cell migration and formation of neuronal layers, as well as in neuronal and glial cell differentiation and synaptogenesis [62, 63]. The staining of β-gal in the trigeminal ganglion (represents one of the first primordia of the neural crest to differentiate in the mesencephalic region), as detected in our study, highlights the role of THs on neuronal and glial cell differentiation. Further, because β-gal was expressed in different areas of the brain (i.e. diencephalon) or in the sense organs primordia at an early stage, our data show that maternal THs are transcriptionally active in the development of these anatomical structures. At E15.5–E17.5 (late stage) when the FTF is finally settled, β-gal expression was detected in different primordia compared to its expression in the early stages, such as small intestine, follicular nerves of the vibrissae, bones, skin (dermatomes), muscle, blood vessels, etc. We hypothesize that these late stages, most THs available to embry–foetal primordia are probably still of maternal origin, because foetal thyroid becomes active only at E17.5.

Similar to the results found in the transient transgenic embryos, β-gal expression was detected in the embryos obtained from the stable transgenic line, both at early and late stages of development. However, the pattern of β-gal expression in the stable embryos was less diffuse compared to the transient transgenic embryos. This may be due to the transgene transmission through germ line. In fact, a proportion of transgenes undergo germ-line heritable epigenetic modifications, including DNA methylation or histone modifications due to the chromatin packaging, which could affect the transgene expression levels by transcriptional repression [64, 65]. Less frequently, the expression levels of the transgene may be influenced by endogenous silencers or enhancers surrounding the regions of insertion [66].

Our stable transgenic line consistently expressed β-gal at the early stages, i.e. in the brain (i.e. diencephalic primordia, medulla oblongata) and sense organs primordia (otic vesicle, olfactory epithelium, retina), whereas at late stages (E15.5–E17.5) this pattern no longer appeared, and the expression was specifically localized in other primordia, i.e. in the bones, follicular nerves of the vibrissae, as well as in the small intestine primordia, but also in the medulla oblongata.

Our results from the stable, as well as from the transient, transgenic embryos highlight the essential role of TH for normal brain development during embry–foetal life, as previously reported [19, 25, 67, 68]. Of relevance, in the rat, changes in
maternal TH availability during early stages of development –

equivalent to the end of the first and beginning of the second

trimester in human beings – irreversibly affect neurogenesis and

radial migration of neurons into the developing cerebral cortex and

hippocampus [19].

To the best of our knowledge, this is the first transgenic mouse model that traces THs action during diencephalon differenti-

ation (prosencephalic regionalization) – the brain region that

includes the thalamus, hypothalamus and epithalamus, which is

involved in the physiological regulation of several biological

processes. Moreover, our data reveal β-gal expression in the

small intestine primordia at E17.5. This result importantly con-

firms the fact that THs are involved in mammalian intestinal

epithelial development, and may affect its fundamental processes

goal and differentiation. Interestingly, hypothyroid animals

display marked crypt villus hyperplasia and thyroidectomy in adult

rats leads to a decrease in jejunal crypt mitotic rate, whereas T3

administration induces mucosal hyperplasia [69–72]. T3 has two

major influences on the adult small intestine, including a trophic

on crypt cells and alteration in the pattern of brush-border

enzyme expression in the villus. In addition, Malo et al. identified

a novel response element that appears to mediate T3-induced

activation of the enterocyte differentiation marker (i.e. intestinal

alkaline phosphatase) [73]. T3 mediates its effects through TRs,

and TRs knockout mice were studied to determine the effects of

T3 on intestine development and differentiation. Although TRβ

knockout mice appear to have no intestinal abnormalities, TRα

knockout mice display marked hypoplasia in the crypts and villi

and decreased levels of digestive enzymes (i.e. lactase, sucrase,

aminopeptidase) [74–77]. TRα therefore regulates intestinal

development and homeostasis by controlling epithelial prolifera-

tion in the crypts. This process involves positive control of the

Wnt/β-catenin pathway [78–79].

Other transgenic mouse models were used to study TH action
during embryo–foetal development. Quigonodon et al. used the

yeast UASHsp68/Gal4/-TRα1/LacZ system and found β-gal expres-
sion in the roof of the midbrain at late stages (E15.5) [53].
Nagasawa et al. used TRβ1/LacZ system and described β-gal expres-
sion in the midbrain, auditory vesicles, limbs and face at early

stages (E9.5–E12.5), and in the root of whisker follicles and

the intestine primordia at E17.5 [80]. The differences in embryonic

sites and stages of transgene expression between our model and

the previous ones described may be explained by the different

types of transgenes used [81].

In our study T3 treatment from E9.5 to E12.5 in hypothyroid

pregnant transgenic mice was able to rescue β-gal expression in

the diencephalon primordium of E12.5 transgenic embryos, repro-
ducing a similar pattern to that observed in the euthyroid trans-

genic mouse embryos. This result highlights that TRE2× transac-
tivation is specifically driven by TH. Furthermore, we showed that

embryo–foetal primordia expressing β-gal by TRE2× transactiva-
tion through TH action are also positive for TRs both at early and

late stages, thus suggesting that TH action may be mediated by

embryonic TRs. However, not all embryonic TR+ areas were β-
gal+; the absence of β-gal expression may suggest that in those

late stages of the foetal rat nervous system development; nevertheless, TRα2 levels were markedly higher [36], thus suggesting that TRα2 might be a critical regulator of TH action by interfering with T3 effect on the expression of brain-specific genes.

In summary, our study shows a tissue-specific ontogenetic expression of TRs as well as a synergic action between maternal TH and embryonic TRs, as early as E11.5 by the regulation of TR2× transcriptional activity (β-gal expression) in the transgenic embryos. TH/TR action presumably regulates the transcription of target genes involved in the development of CNS (i.e. diencephalon differentiation), intestine and other embryo–foetal primordia before FTF is active. These results are reinforced by the finding that when the maternal thyroid gland is functionally blocked (hypothyroidism: low T3 and T4 and high TSH), β-gal expression is completely absent despite the presence of TRs, and is rescued with T3 treatment.

In conclusion, our transgenic mouse model may be a reliable tool to investigate molecular mechanisms underlying maternal TH action during early and late embryo–foetal development. It may also represent a useful model to analyse maternal hypothyroidism, transient gestational hypothyroxinemia or hypothyroidism effects during embryo–foetal development. This model may have clinical relevance and may be employed to design end-point assays whereby new molecules affecting or mimicking TH action in early and late embryo–foetal development could be tested.

Acknowledgements

C.N. (M.D., Ph.D.) was a recipient of a doctorate fellowship (Ph.D. program in Experimental Endocrinology and Metabolic Diseases, Italy). This work was supported by MIUR (PRIN Grants) to A.P. (principal investigator) and C.N. (co-investigator) and by Catholic University Grants to A.P. A.V. was supported by MIUR (PRIN Grants) and C.T. was supported by Telethon Foundation (Grant B55). We thank Dr. Samuel Refetoff (Professor Emeritus of Medicine and Pediatrics, University of Chicago, Chicago, IL, USA) for TSH, total T3 and T4 assays and for critical reading of the manuscript. We are grateful to Mrs. Daniela Martinuzzi, Laura Tatangelo and GianCarlo Cortese for technical assistance. We thank Dr. Dan Li at the Core Facility of Vascular Biology Research Center, BIDMC/Harvard Medical School (Boston, MA, USA) for genotyping assays by real-time PCR. We thank for helpful suggestions Drs. Silvia Bacchetti, Simona Nanni, Annalisa Grasselli (Department of Experimental Oncology, Regina Elena Cancer Institute, Roma, Italy), Lucius Chiariaviglio (BIDMC/Harvard Medical School, Boston, MA, USA) and Michal Mekel (Department of General Surgery, Rambam-Health Care Campus, Haifa, Israel).

References

23. Dowling AL, Martz GU, Leonard JL, Zoeller RT. Acute changes in maternal

© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
The effect of mitotic rate of the intestinal mucosa of the growth hormone and thyroxine on the following induced hyperthyroidism in the rat. Virchows Arch B Cell Pathol. 1970; 6: 40128–35.


97. Forrest D, Reh TA, Rusch A. Neurodevelopmental control by thyroid hormone.


